Deoxyribonucleic Acid (DNA) Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The deoxyribonucleic acid vaccines market size is expected to grow from USD 546.03 million in 2025 to USD 581.74 million in 2026 and is forecast to reach USD 822.92 million by 2031 at 7.18% CAGR over 2026-2031. This report is segmented by Type (Human, Animal), Vaccine Purpose (Prophylactic, Therapeutic), Technology (Plasmid, Linear, Minicircle, Other), Delivery Method (Electroporation, and More), Route of Administration (Intradermal, and More), Indication (Infectious Diseases, and More), End User (Hospitals, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Deoxyribonucleic Acid (DNA) Vaccines Market Trends and Insights

Faster Response to Emerging and Re-emerging Pathogens

DNA vaccines can use a validated plasmid backbone with a newly selected antigen sequence, which can shorten the early design stage after a pathogen is genetically characterized. INOVIO moved from sequence selection to a first human dose in 82 days during the COVID-19 response. The INO-4500 Phase 1b study in 220 adults in Ghana reported measurable humoral and cellular responses after intradermal administration with electroporation. This result supports continued development against pathogens such as the Lassa virus, where a rapid response platform may have practical value. The DNA vaccines market can also benefit when preparedness programs create reusable manufacturing and regulatory experience before an outbreak requires broad deployment. Lower temperature sensitivity than many mRNA products can further support use in areas with constrained cold-chain infrastructure.

Growing Therapeutic Oncology and Personalized Vaccine Pipelines

Therapeutic DNA vaccines are being developed to direct immune responses against tumor-specific mutations rather than to prevent an infection. A 2026 Phase 1 glioblastoma study reported vaccine-specific T-cell responses from a personalized DNA vaccine that targeted up to 40 spatially distributed neoantigens. Research on neoantigen vaccines has also described the potential for durable T-cell immunity, although clinical benefit must be assessed in each program. Touchlight reported first patient dosing in the NEOVACC Phase I personalized lung cancer vaccine trial in July 2026 using its cell-free dbDNA platform. Faster production may make patient-specific products more workable for tumors that progress quickly. This activity supports the 9.2% forecast CAGR for oncology within the DNA vaccines market.

Lower Human Immunogenicity With Conventional Injection

Conventional intramuscular and subcutaneous injection has produced weaker immune responses for many human DNA vaccine candidates. Published clinical data have indicated that measurable responses may require a 2 mg DNA dose, compared with 30 to 100 μg doses for mRNA COVID-19 vaccines. DNA must reach the cell nucleus, and ordinary injection does not assist this process. Electroporation can improve cellular uptake, but it adds equipment and administration requirements. A 2025 preclinical study reported durable protection in mice after an LNP-formulated H5N1 plasmid DNA vaccine. LNP formulation may reduce this limitation, but it still requires clinical validation and a scalable manufacturing process for human programs.

Other drivers and restraints analyzed in the detailed report include:

• Greater Demand for Stable, Scalable Vaccine Platforms
• Expansion of Veterinary and Zoonotic Disease Prevention
• Limited Human Commercial Validation and Reimbursement Precedent

Segment Analysis

Human DNA vaccines accounted for 61.83% of revenue in 2025. This position reflects clinical activity in HPV-related disease, infectious diseases, and oncology. The human segment includes programs for MERS-CoV, Lassa virus, Ebola, influenza, and cancer. Animal vaccines supplied the remaining revenue and remain the source of fully commercialized product experience for the platform. Products for canine melanoma, equine disease, and salmon aquaculture have provided a reference point for manufacturing and regulatory practice. This history helps developers explain how DNA-based products can be made and administered.

Human DNA vaccines are forecast to grow at an 8.51% CAGR from 2026 to 2031. VGX-3100 reported positive topline results from its China Phase III study in May 2026, including 207 participants at 22 tertiary hospitals and achievement of the primary endpoint. Fosun Wanbang obtained Greater China commercialization rights in January 2026 under a deal valued at CNY 800 million, equivalent to USD 113 million, in upfront and milestone payments plus double-digit royalties. These terms provide a useful commercial reference for the human DNA vaccines market in Asia-Pacific. Animal programs can move through shorter development pathways and face different evidence requirements. They are likely to remain an important near-term contributor while human products mature.

Prophylactic vaccines accounted for 65.38% of revenue in 2025. Pandemic preparedness, infectious disease prevention, and the established animal health base supported that position. Therapeutic programs are forecast to grow at a 9.07% CAGR through 2031. Their growth is tied mainly to oncology programs that seek to stimulate responses against neoantigens. This use differs from prevention because each patient may need a distinct construct. It also creates different demands for manufacturing turnaround and clinical evidence.

Personalized therapeutic vaccines often require manufacturing from biopsy material to a finished dose in less than 4 weeks. The NEOVACC trial demonstrates how cell-free production is being used to address this operational need. Therapeutic programs for allergy and autoimmune disease remain early in development. The available input also identifies patient selection as a key issue for non-small cell lung cancer. Companion diagnostics could therefore be needed before therapeutic vaccines gain broad use. The DNA vaccines industry may see a higher-value product mix if oncology candidates establish meaningful clinical benefit. That opportunity still depends on response prediction, manufacturing consistency, and payer acceptance.

Plasmid DNA held 72.16% of the technology platform segment in 2025. Its share reflects established cGMP experience across bacterial fermentation-based manufacturing networks. Developers know the process expectations for plasmid products entering later clinical stages. Plasmid DNA is also forecast to grow at a 9.18% CAGR through 2031. The growth rate reflects the volume of clinical programs, especially in oncology and infectious diseases. It does not remove the need to improve delivery and simplify manufacturing.

Linear DNA and minicircle DNA are being developed as alternatives to conventional plasmids. They can address concerns related to antibiotic resistance markers and bacterial fermentation artifacts. Touchlight received an MHRA GMP license for cell-free dbDNA manufacturing in January 2025. Applied DNA Sciences completed its LineaDNA GMP facility buildout in January 2025. These platforms may give developers more manufacturing options as programs move into later studies. MIDGE vectors and DNA origami platforms remain preclinical and add to the longer-term technology range.

Complete Report Scope:

• By Type
  • Human DNA Vaccines
  • Animal DNA Vaccines
• By Vaccine Purpose
  • Prophylactic DNA Vaccines
  • Therapeutic DNA Vaccines
• By Technology Platform
  • Plasmid DNA Vaccines Technology
  • Linear DNA Vaccines Technology
  • Minicircle DNA Vaccines Technology
  • Other DNA Constructs
• By Delivery Method
  • Electroporation
  • Needle-Free Injection
  • Suction-Based Delivery
  • Lipid and Nanoparticle Delivery
  • Liposome and Polymer Delivery
  • Other Delivery Methods
• By Route of Administration
  • Intradermal
  • Intramuscular
  • Subcutaneous
  • Oral and Mucosal
  • Other Routes of Administration
• By Indication
  • Infectious Diseases
  • Oncology
  • Allergies and Autoimmune Conditions
  • Other Human Indications
  • Veterinary Diseases
• By End User
  • Hospitals and Clinics
  • Veterinary Hospitals and Clinics
  • Government and Public-Health Suppliers
  • Research Institutes and Academic Centers
  • Pharmaceutical and Biotechnology Companies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.12% of the global DNA vaccines market in 2025. The region has a high concentration of clinical developers, plasmid CDMOs, and delivery technology suppliers. Canada and Alberta committed USD 198.5 million to Entos Pharmaceuticals' Edmonton manufacturing project in 2025. The planned site targets a capacity of 10 million vaccine doses per year. In the United States, INOVIO reported that pre-licensure inspections for INO-3107 were complete in its second-quarter 2026 update. Mexico remains a smaller participant, with activity centered on government health procurement rather than domestic product development.

Europe is the second-largest regional market. The MHRA granted the first GMP license for cell-free enzymatic DNA production to Touchlight's Hampton facility in January 2025. INO-3107 has an EMA Orphan Drug designation and a UK Innovation Passport under the ILAP pathway. Germany, France, and Italy have established biologics manufacturing capabilities. NorthX Biologics is supporting Amarna Therapeutics as it prepares Nimvec AM510 for first-in-human studies expected by 2027. European developers and academic groups add to the region's clinical and manufacturing depth.

Asia-Pacific is forecast to grow at an 8.76% CAGR from 2026 to 2031. India established a key precedent through ZyCoV-D, the first approved human plasmid DNA vaccine, under the National Biopharma Mission. China adds momentum through VGX-3100 Phase III results and Fosun Wanbang's Greater China commercialization arrangement. Japan, Australia, and South Korea contribute to pipeline and clinical trial activity. The Middle East, Africa, and South America remain smaller markets. Thermal stability can support a longer-term opportunity in these locations as public-health systems expand.

List of Companies Covered in this Report:

• Applied DNA Sciences, Inc.
• AnGes, Inc.
• AGC Biologics
• Aldevron LLC
• Boehringer Ingelheim Animal Health USA Inc.
• Eurogentec S.A.
• Enzene Biosciences Limited
• Entos Pharmaceuticals Inc.
• Genexine, Inc.
• GeneOne Life Science, Inc.
• INOVIO Pharmaceuticals, Inc.
• Ichor Medical Systems, Inc.
• LineaRx, Inc.
• NorthX Biologics AB
• PharmaJet, Inc.
• Takara Bio
• Touchlight Genetics Ltd.
• Takis Biotech S.r.l.
• VGXI, Inc.
• Waisman Biomanufacturing
• Zydus Lifesciences Limited
• Zoetis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support